Curantil - instructions for use, reviews, analogs and forms of release (tablets N 25 mg and 75 mg) drugs for the treatment of circulatory disorders and prevention of thrombosis in adults, children and pregnancy (in planning). Composition and Contraindications

In this article, you can read the instructions for using the drug Currantil. Comments of visitors of the site - consumers of this medication, as well as opinions of doctors of specialists on the use of Courantil in their practice are presented. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogues of Kurantil with available structural analogues.Use to treat circulatory disorders and prevent thrombosis in adults, children, as well as during pregnancy and lactation. Composition and contraindications of the drug.

Currantil vasodilator of myotropic action. Has a retarding effect on the aggregation of platelets, improves microcirculation.

Dipiridamol (active ingredient of the drug Kurantil) expands arterioles in the coronary blood flow system, when taken in high doses - and in other parts of the circulatory system. However, unlike organic nitrates and calcium antagonists, the expansion of larger coronary vessels does not occur.

The vasodilating effect of Dipyridamole is due to two different mechanisms of inhibition: suppression of adenosine capture and inhibition of phosphodiesterase.

In vivo, adenosine is found at a concentration of approximately 0.15-0.20 μmol. This level is maintained due to the dynamic balance between ejection and re-capture. Dipyridamole inhibits the capture of adenosine by endothelial cells, erythrocytes and platelets. After the introduction of Curantil, an increase in the concentration of adenosine in the blood and an increase in adenosine-mediated vasodilatation are found.In higher doses, inhibition of platelet aggregation caused by adenosine occurs, and the tendency to thrombogenesis decreases.

The decomposition of cAMP and cGMP, suppressing platelet aggregation, occurs in platelets under the action of the corresponding phosphodiesterases. In high concentrations, dipyridamole inhibits both phosphodiesterases, in therapeutic concentrations in the blood - only cGMP phosphodiesterase. As a result of stimulation of corresponding cycles, the power of cAMP synthesis increases.

As a derivative of pyrimidine, dipyridamole is an inducer of Interferon and has a modulating effect on the functional activity of the interferon system, increases the decreased production of interferon alfa and gamma-leukocytes of blood. The drug increases the nonspecific resistance to viral infections.

Composition

Dipyridamole + auxiliary substances.

Pharmacokinetics

Dipyridamole almost completely binds to plasma proteins. Dipyridamole accumulates in the heart and in red blood cells. Dipyridamole is metabolized in the liver by binding to glucuronic acid. It is excreted with bile in the form of monoglyukuronide.

Indications

• treatment and prevention of cerebral circulation disorders by ischemic type;
• encephalopathy;
• primary and secondary prevention of IHD, especially with intolerance to acetylsalicylic acid;
• prevention of arterial and venous thrombosis and treatment of their complications;
• prevention of thromboembolism after surgery for prosthetic heart valves;
• prevention of placental insufficiency in a complicated pregnancy;
• when planning pregnancy;
• disorders of microcirculation of any type (as part of complex therapy);
• prevention and treatment of influenza, ARVI (as an inducer of interferon and immunomodulator) - for taking the drug at a dose of 25 mg.

Forms of release

The tablets covered with a cover of 25 mg.

Tablets coated with N 25 (25 mg).

Tablets coated with N 75 (75 mg).

Instructions for use and dosage

The dose of the drug is selected depending on the severity of the disease and the individual reaction of the patient.

With IHD, taking 75 mg 3 times a day is recommended. If necessary, the daily dose can be increased under the supervision of a doctor.

For the prevention and treatment of cerebral circulation disorders, as well as for prevention, 75 mg 3-6 times a day are prescribed.The maximum daily dose is 450 mg.

To reduce the aggregation of platelets, Kurantil is prescribed in a dose of 75-225 mg per day in several doses. In severe cases, the dose may be increased to 600 mg per day.

For the prevention of influenza and acute respiratory viral infections, especially during epidemics, Curantyl N25 and Curantil 25 are given 50 mg (2 tablets or 2 tablets) per day in a single dose. The drug is taken once a week for 4-5 weeks.

To prevent recurrence of acute respiratory viral infections in frequently ill patients with respiratory viral infections, Kurantil N25 and Curantil 25 are prescribed 100 mg per day (two tablets or two drops a day, with an interval between doses of 2 hours). The drug is taken once a week for 8-10 weeks.

Tablets should be taken on an empty stomach, not breaking down and not biting, squeezed with a small amount of liquid. The duration of treatment is determined by the doctor.

Side effect

• palpitation;
• tachycardia (especially with the simultaneous use of other vasodilators);
• bradycardia;
• flushes of blood to the face;
• hyperemia of the facial skin;
• syndrome of coronary stealing (when using the drug in a dose of more than 225 mg per day);
• a decrease in blood pressure;
• nausea, vomiting;
• diarrhea;
• pain in the epigastric region;
• thrombocytopenia, changes in the functional properties of platelets;
• bleeding;
• increased bleeding during or after surgery;
• dizziness;
• noise in the head;
• headache;
• skin rash;
• hives;
• weakness;
• feeling of ear stiffness;
• myalgia;
• rhinitis.

Contraindications

• acute myocardial infarction;
• unstable angina;
• common stenosing coronary artery atherosclerosis;
• subaortic stenosis of the aorta;
• heart failure in the stage of decompensation;
• arterial hypotension;
• collapse;
• severe arterial hypertension;
• severe heart rhythm disturbances;
• chronic obstructive pulmonary disease;
• chronic renal failure;
• liver failure;
• hemorrhagic diathesis;
• diseases with an increased risk of bleeding (including peptic ulcer disease of the stomach and duodenum);
• hypersensitivity to the components of the drug.

Application in pregnancy and lactation

Possible use of the drug during pregnancy according to the indications.

The use of the drug during lactation is possible only if the expected benefit of the treatment exceeds the possible risk.

Use in children

Curantil is not recommended for children under 12 years of age due to lack of sufficient clinical experience of its use.

special instructions

With the simultaneous use of tea or coffee (contain xanthine derivatives), the vasodilating effect of Curantil may decrease.

Impact on the ability to drive vehicles and manage mechanisms

Care should be taken when driving vehicles and controlling mechanisms, because as a result of a fall in blood pressure, the ability to concentrate attention and the speed of psychomotor reactions may worsen with the use of Courantil.

Drug Interactions

With the simultaneous use of Curantil with anticoagulants or acetylsalicylic acid, the antithrombotic effect of the latter increases and, accordingly, the risk of hemorrhagic complications.

With simultaneous application, Curantil enhances the effect of antihypertensive drugs.

When combined, Couantil can weaken the anticholinergic effects of cholinesterase inhibitors.

With the simultaneous use of xanthine derivatives weaken the vasodilator actionCurantila.

Analogues of the drug Curantil

Structural analogs for the active substance:

• Dipyridamole;
• Curantyl N 25;
• Curantyl N 75;
• Parsedil;
• Persantin;
• Sanomil Sanovel.

Similar medicines:

Other medicines: